Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis

Koji Sasaki, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Koichi Takahashi, Marina Konopleva, Gautam Borthakur, Guillermo Garcia-Manero, William Wierda, Naval Daver, Preetesh Jain, Toshihisa Satta, Sherry Pierce, May Beth Rios, Jorge E. Cortes

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)e324-e327
JournalHaematologica
Volume101
Issue number8
DOIs
StatePublished - Jul 31 2016
Externally publishedYes

Keywords

  • Chronic myeloid leukemia
  • Dasatinib
  • High-dose imatinib
  • Nilotinib

ASJC Scopus subject areas

  • Hematology

Cite this

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis. / Sasaki, Koji; Kantarjian, Hagop; Jabbour, Elias; Ravandi, Farhad; Takahashi, Koichi; Konopleva, Marina; Borthakur, Gautam; Garcia-Manero, Guillermo; Wierda, William; Daver, Naval; Jain, Preetesh; Satta, Toshihisa; Pierce, Sherry; Rios, May Beth; Cortes, Jorge E.

In: Haematologica, Vol. 101, No. 8, 31.07.2016, p. e324-e327.

Research output: Contribution to journalLetter

Sasaki, K, Kantarjian, H, Jabbour, E, Ravandi, F, Takahashi, K, Konopleva, M, Borthakur, G, Garcia-Manero, G, Wierda, W, Daver, N, Jain, P, Satta, T, Pierce, S, Rios, MB & Cortes, JE 2016, 'Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis', Haematologica, vol. 101, no. 8, pp. e324-e327. https://doi.org/10.3324/haematol.2015.139089
Sasaki, Koji ; Kantarjian, Hagop ; Jabbour, Elias ; Ravandi, Farhad ; Takahashi, Koichi ; Konopleva, Marina ; Borthakur, Gautam ; Garcia-Manero, Guillermo ; Wierda, William ; Daver, Naval ; Jain, Preetesh ; Satta, Toshihisa ; Pierce, Sherry ; Rios, May Beth ; Cortes, Jorge E. / Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis. In: Haematologica. 2016 ; Vol. 101, No. 8. pp. e324-e327.
@article{d56d3743299a43bea2c8c0ac14ec4069,
title = "Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis",
keywords = "Chronic myeloid leukemia, Dasatinib, High-dose imatinib, Nilotinib",
author = "Koji Sasaki and Hagop Kantarjian and Elias Jabbour and Farhad Ravandi and Koichi Takahashi and Marina Konopleva and Gautam Borthakur and Guillermo Garcia-Manero and William Wierda and Naval Daver and Preetesh Jain and Toshihisa Satta and Sherry Pierce and Rios, {May Beth} and Cortes, {Jorge E.}",
year = "2016",
month = "7",
day = "31",
doi = "10.3324/haematol.2015.139089",
language = "English (US)",
volume = "101",
pages = "e324--e327",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "8",

}

TY - JOUR

T1 - Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis

AU - Sasaki, Koji

AU - Kantarjian, Hagop

AU - Jabbour, Elias

AU - Ravandi, Farhad

AU - Takahashi, Koichi

AU - Konopleva, Marina

AU - Borthakur, Gautam

AU - Garcia-Manero, Guillermo

AU - Wierda, William

AU - Daver, Naval

AU - Jain, Preetesh

AU - Satta, Toshihisa

AU - Pierce, Sherry

AU - Rios, May Beth

AU - Cortes, Jorge E.

PY - 2016/7/31

Y1 - 2016/7/31

KW - Chronic myeloid leukemia

KW - Dasatinib

KW - High-dose imatinib

KW - Nilotinib

UR - http://www.scopus.com/inward/record.url?scp=84980410087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980410087&partnerID=8YFLogxK

U2 - 10.3324/haematol.2015.139089

DO - 10.3324/haematol.2015.139089

M3 - Letter

C2 - 27175025

AN - SCOPUS:84980410087

VL - 101

SP - e324-e327

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -